title: Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women.
abstract: OBJECTIVE
  The aim of the present study was to determine if the favourable cardiopulmonary and metabolic benefits induced by exercise training (ET) programme are maintained after its cessation.
  
  
  METHODS
  Thirty-two young overweight polycystic ovary syndrome (PCOS) women matched for age and body mass index (BMI) with other 32 PCOS patients was enrolled. The first group [PCOS-T (trained)] underwent 24-week ET programme, whereas the second [PCOS-DT (detrained)] underwent 12-week ET programme followed by 12-week detraining period.
  
  
  METHODS
  At baseline, after 12- and 24-week follow-up, all PCOS women were studied for their hormonal (ovarian and adrenal androgens), metabolic (glucose and insulin) and lipid profile, and underwent cardiopulmonary exercise test.
  
  
  RESULTS
  After the initial 12-week ET programme, both PCOS-T and PCOS-DT groups, without differences between groups, showed a similar significant (P < 0.05) improvement in BMI, fasting insulin, areas under curve insulin (AUC(INS)), glucose and insulin AUC (AUC(GLU/INS)), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C) and maximal oxygen consumption at cardiopulmonary exercise test (VO2max). At 24-week follow-up, PCOS-T group showed a significant (P < 0.05) improvement in BMI, fasting insulin, AUC(INS), AUC(GLU/INS), LDL-C, HDL-C and VO2max, in comparison to baseline and 12-week follow-up. At same follow-up visit, the all parameters resulted significantly (P < 0.05) worsened in PCOS-DT group in comparison to 12-week follow-up and PCOS-T group. In PCOS-DT group, no parameter assessed at 24-week follow-up was significantly different in comparison with baseline.
  
  
  CONCLUSIONS
  In young PCOS women, 12-week detraining resulted in a complete loss of the favourable adaptations obtained after ET.
authors.affiliation: Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy. francescoorio@virgilio.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Orio
authors.forename: Francesco
authors.initials: F
authors.lastname: Giallauria
authors.forename: Stefano
authors.initials: S
authors.lastname: Palomba
authors.forename: Francesco
authors.initials: F
authors.lastname: Manguso
authors.forename: Marcello
authors.initials: M
authors.lastname: Orio
authors.forename: Domenico
authors.initials: D
authors.lastname: Tafuri
authors.forename: Gaetano
authors.initials: G
authors.lastname: Lombardi
authors.forename: Enrico
authors.initials: E
authors.lastname: Carmina
authors.forename: Annamaria
authors.initials: A
authors.lastname: Colao
authors.forename: Carlo
authors.initials: C
authors.lastname: Vigorito
mesh_terms: D001786:Blood Glucose; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D015444:Exercise / Q000502:physiology*; D005260:Female; D006334:Heart Function Tests; D006801:Humans; D007328:Insulin / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D050177:Overweight; D010101:Oxygen Consumption; D011085:Polycystic Ovary Syndrome / Q000378:metabolism*; D012129:Respiratory Function Tests; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol